Clinical trials: Schizophrenia
Schizophrenia
Sertindole in Asian Patients With Schizophrenia
The purpose of this study is to assess the efficacy and safety of sertindole in patients with schizophrenia in Asia.
- Trial name
- NCT00864045
- Testing
- Sertindole, Olanzapine
- Where
- China
- Volunteers
- 394 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia, Psychotic Disorders
A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With Schizophrenia
The purpose of the study is to compare the effectiveness and safety of a long-acting injectable formulation of risperidone (an antipsychotic medication) versus placebo for the treatment of the symptoms of schizophrenia over a…
- Trial name
- NCT00253136
- Testing
- risperidone
- Volunteers
- 458 people
- Sponsor
- Janssen, LP
Schizophrenia
Efficacy of Lu 31-130 in Patients With Schizophrenia
The main purpose with the study is to explore the efficacy and safety of Lu 31-130 in patients suffering from schizophrenia compared to a standard antipsychotic drug.
- Trial name
- NCT00770744
- Testing
- Zicronapine, Olanzapine
- Where
- 21 sites in Czechia, France and 6 more
- Volunteers
- 93 people
- Sponsor
- H. Lundbeck A/S
Schizophrenic Disorders
Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone
The trial is designed to assess the long term subjective well-being in schizophrenic outpatients treated with quetiapine XR (extended release) or oral risperidone at flexible dose in a naturalistic setting over a period of one…
- Trial name
- RECOVER (NCT00600756)
- Testing
- Quetiapine XR, Risperidone
- Where
- 116 sites in Belgium, Brazil and 12 more
- Volunteers
- 798 people
- Sponsor
- AstraZeneca
Schizophrenia
Neuromodulation for Schizophrenia
Our proposed study employs a novel approach to determine the clinical and functional imaging effects of brainstem neuromodulation, with an investigational study device, on illness awareness in schizophrenia - a significant…
- Trial name
- NCT05580211
- Testing
- Non-invasive brainstem modulation device (stimulation Randomized), Non-invasive brainstem modulation device (stimulation-Open Label)
- Where
- Canada
- Volunteers
- 34 people
- Sponsor
- Scion NeuroStim
Schizophrenia
A Study to Assess Learning Performance in Patients With Schizophrenia and Young and Elderly Healthy Volunteers
The purpose of this study is to measure and contrast implicit and explicit learning performance in patients with schizophrenia relative to young and elderly healthy volunteers.
- Trial name
- NCT01788436
- Testing
- Cognitive Test Battery 1, Cognitive Test Battery 2
- Where
- Belgium
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Schizophrenic Disorders
A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia
This study determined if a single dose of LY2140023 (pomaglumetad methionil) affects the electrical activity in the heart in participants with schizophrenia.
- Trial name
- NCT01606436
- Testing
- LY2140023, Moxifloxacin
- Where
- 8 sites in United States
- Volunteers
- 86 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia
Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)
To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of schizophrenia
- Trial name
- NCT02970292
- Testing
- Pimavanserin
- Where
- 105 sites in United States, Bulgaria and 8 more
- Volunteers
- 396 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Schizophrenia
An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication
An Extension study to a clinical study that will continue to evaluate the effectiveness and safety of SEP-363856 in people with schizophrenia that switch to SEP-363856 from their current antipsychotic medication.
- Trial name
- NCT05741528
- Testing
- SEP-363856
- Where
- 16 sites in United States
- Volunteers
- 75 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.
- Trial name
- NCT07288567
- Testing
- KarXT
- Where
- 37 sites in United States, Colombia and 2 more
- Volunteers
- 166 people
- Sponsor
- Bristol-Myers Squibb
Negative Symptoms in Schizophrenia, Schizophrenia
NST-SPARK: Preliminary Study of an Augmented Reality (AR) App Delivering Recovery-Oriented Cognitive Therapy for Negative Symptoms in Schizophrenia
This study evaluates the feasibility and acceptability of a prototype for NST-SPARK (version 1.5). This is an augmented reality (AR) mobile phone application that uses Recovery-oriented Cognitive Therapy (CT-R) to target negative…
- Conditions
- Negative Symptoms in Schizophrenia, Schizophrenia, Schizoaffective Disorder
- Trial name
- NST-SPARK-1b (NCT06653829)
- Testing
- SPARK
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- North Shore Therapeutics, Inc.
Schizophrenia
eMotiph: E-mental Health Solution for Patients With Schizophrenia
Although the main objective of current schizophrenia intervention programs is the reduction of symptoms, its rates are around 36%, and recovery rates are 16.5%.
- Trial name
- NCT05345977
- Testing
- eMotiph
- Where
- Spain
- Volunteers
- 7 people
- Sponsor
- Grupo Pulso
Schizophrenia
A Study of Paliperidone Enantiomer Disposition With Different Formulations and the Bioavailability of Immediate- and Extended-release Paliperidone
The purpose of this study is to characterize the pharmacokinetics of paliperidone in plasma and urine after intravenous (i.v.) administration of the racemate, administration of the immediate-release (IR) racemate oral solution…
- Trial name
- NCT00796276
- Testing
- IR OROS paliperidone and ER OROS paliperidone
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Bipolar I Disorder
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.
- Trial name
- NCT05648591
- Testing
- Iloperidone
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia
Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy
- Trial name
- NCT07101094
- Testing
- xanomeline and trospium chloride (X/T) therapy
- Where
- 20 sites in United States
- Volunteers
- 300 people
- Sponsor
- Bristol-Myers Squibb
Psychotic Disorders, Schizophrenia
Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia
The purpose of this study is to explore the pharmacokinetics, safety and tolerability of a 4-week long-acting injectable (LAI) formulation of risperidone after single intramuscular (i.m.) injection of 75 mg risperidone LAI in the…
- Trial name
- NCT00821600
- Testing
- risperidone IR and LAI formulation
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
NIS to Observe Improvement in Global Assessment of Functioning in Patients With Schizophrenia
The purpose of the study is to monitor the general functional changes among patients with schizophrenia, treated with atypical antipsychotics dosed once daily for a period of 6 months.The primary study objective is to compare…
- Trial name
- NCT00833456
- Where
- 14 sites in Slovenia
- Volunteers
- 106 people
- Sponsor
- AstraZeneca
Schizophrenia
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
The study will assess the use of paliperidone palmitate compared with oral antipsychotic treatment in delaying time to a protocol-defined treatment failure over 15 months, in patients diagnosed with schizophrenia who have been…
- Trial name
- NCT01157351
- Testing
- paliperidone, risperidone, haloperidole
- Where
- 56 sites in United States, Puerto Rico
- Volunteers
- 450 people
- Sponsor
- Janssen Scientific Affairs, LLC
Schizophrenia
Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults
This will be a multicenter, randomized, double-blind, placebo and active comparator parallel-controlled study designed to assess the safety and efficacy of VV119 (2.0 to 6.0 mg) for the treatment of adult participants diagnosed…
- Trial name
- NCT07703956
- Testing
- VV119 2mg, VV119 4mg, VV119 6mg
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Vigonvita Life Sciences
Schizophrenia Disorders
The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting Injection Following a Single Administration in Healthy Subjects/Patients With Schizophrenia.
Study to evaluate the safety and tolerability of single ascending doses of brexpiprazole long-acting injection in healthy subjects/patients with schizophrenia.
- Trial name
- NCT06674694
- Testing
- Brexpiprazole long-acting injection
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Sichuan Kelun Pharmaceutical Co.,Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.